Hayoung Hwang
Daegu, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Synthesis of 3-desoxycollinoketone B and its ability to reduce Alzheimer-associated misfolded proteins.
Journal: Nature communications
Published: February 24, 2025
Discovery of the therapeutic potential of PPARδ agonist bearing 1,3,4- thiadiazole in inflammatory disorders.
Journal: European journal of medicinal chemistry
Published: July 02, 2024
Engineering small-molecule analogues of altiratinib via CREB-regulated transcription co-activator 3-target screening for the development of potent and safe topical therapeutics against skin hyperpigmentary diseases.
Journal: Clinical and translational medicine
Published: October 11, 2023
Exploration of Tetrahydroisoquinoline- and Benzo[c]azepine-Based Sphingosine 1-Phosphate Receptor 1 Agonists for the Treatment of Multiple Sclerosis.
Journal: Journal of medicinal chemistry
Published: July 25, 2023
Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis.
Journal: Journal of medicinal chemistry
Published: January 25, 2022
The translocator protein ligands as mitochondrial functional modulators for the potential anti-Alzheimer agents.
Journal: Journal of enzyme inhibition and medicinal chemistry
Published: March 23, 2021
Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors.
Journal: Journal of medicinal chemistry
Published: January 11, 2021
An orally available inverse agonist of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancer.
Journal: European journal of medicinal chemistry
Published: March 11, 2020
Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model.
Journal: Neuropharmacology
Published: September 17, 2019
Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes.
Journal: Bioorganic & medicinal chemistry letters
Published: February 12, 2019
Last Updated: 09/26/2026